enalapril has been researched along with Dyslipidemias* in 1 studies
1 other study(ies) available for enalapril and Dyslipidemias
Article | Year |
---|---|
[Erythrocyte aggregation in patients with arterial hypertension and dyslipidemia treated with pravastatin].
The aim of the study was to evaluate effect of pravastatin therapy on erythrocyte aggregation in patients with arterial hypertension and dyslipidemia. It included 81 middle-aged patients with grade I-II AH (risk 3) and type IIb dyslipidemia. Control group consisted of 26 age-matched healthy subjects. 47 patients received pravastatin at a dose of 20 mg (in the evening) and 34 one were given placebo plus analapril (10 mg twice daily). Clinical and laboratory parameters were evaluated before, 4, 12, and 52 weeks after therapy. Statistical analysis of the results was performed with the use of Student's t-test. The study demonstrated increased erythrocyte aggregation in patients with arterial hypertension and dyslipidemia, abnormal blood lipid spectrum and lipid composition of erythrocyte membranes, activation of lipid peroxidation. Pravastatin therapy during 52 weeks optimized the lipid composition and their peroxidation in plasma and erythrocytes; erythrocyte aggregation decreased. It is concluded that pravastatin therapy of AH with dyslipidemia during a year significantly decreases erythrocyte aggregation to the near-normal level. Topics: Anticholesteremic Agents; Antihypertensive Agents; Biological Availability; Drug Monitoring; Dyslipidemias; Enalapril; Erythrocyte Aggregation; Erythrocyte Membrane; Erythrocytes; Female; Humans; Hypertension; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Severity of Illness Index; Treatment Outcome | 2014 |